Q-omics provides the consensus-scored SNRNP48 profile across patient tissues and cancer cell-line models. SNRNP48 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SNRNP48 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, SNRNP48 RNA expression shows 20,457 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, HNSC, and ACC as cancer lineages where SNRNP48 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRNP48 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRNP48 survival associations across molecular data types. SNRNP48 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRNP48 RNA expression–survival associations across cancer types. High SNRNP48 expression shows unfavorable associations in ACC, KIRP and LIHC, but favorable associations in UCS, KIRC and READ. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for SNRNP48 RNA expression.
This table summarizes SNRNP48 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SNRNP48. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRNP48 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, STAD, LIHC and COAD. The HNSC box plot shows higher SNRNP48 RNA expression in tumor versus normal tissue (log2 FC = +0.673, t-test p < 0.001).
This table shows molecular features associated with SNRNP48 in patient tissues and cancer cell lines. In patient samples, SNRNP48 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNRNP48 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
